A Phase 1 Clinical Trial to Evaluate the Immunogenicity of AIDSVAX B/E Bivalent gp120 Vaccine and MVA/HIV62B in Healthy, HIV-1-Uninfected Adult Participants Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

Trial Profile

A Phase 1 Clinical Trial to Evaluate the Immunogenicity of AIDSVAX B/E Bivalent gp120 Vaccine and MVA/HIV62B in Healthy, HIV-1-Uninfected Adult Participants Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs HIV gp120 vaccine (Primary) ; MVA-HIV62 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Aug 2017 Planned number of patients changed from 100 to 30, as reported in a GeoVax Labs media release.
    • 10 Jun 2017 Biomarkers information updated
    • 27 Mar 2017 According to a GeoVax media release, Information from this trial will contribute to the design of future human clinical trials testing GOVX-B11 in the presence and absence of newer gp120 proteins, which are currently being cGMP manufactured.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top